Overview

Utidelone Capsule Combined with Capecitabine and Oxaliplatin in First-line Treatment of PD-L1-negative Gastric or Gastroesophageal Junction Adenocarcinoma Patients

Status:
NOT_YET_RECRUITING

Trial end date:
2030-09-01

Target enrollment:

Participant gender:

Summary

This is a multi-national, open-label, randomized, seamless phase II/III clinical study of UTD2 combined with capecitabine and oxaliplatin to evaluate the efficacy and safety in patients with PD-L1-negative locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma untreated with systemic treatment in advanced setting.

Phase:

PHASE2

Details

Lead Sponsor:

Beijing Biostar Pharmaceuticals Co., Ltd.

Treatments:

Capecitabine
Oxaliplatin